naltrexone has been researched along with Colitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dicay, M; Fichna, J; Janecka, A; Lewellyn, K; MacNaughton, WK; Storr, MA; Zjawiony, JK | 1 |
| Braude, MC; Morrison, JM | 1 |
1 review(s) available for naltrexone and Colitis
| Article | Year |
|---|---|
Preclinical toxicity studies of naltrexone.
Topics: Administration, Oral; Animals; Body Weight; Colitis; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Fertility; Haplorhini; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Naloxone; Naltrexone; Rats; Reproduction; Rhinitis; Teratogens | 1976 |
1 other study(ies) available for naltrexone and Colitis
| Article | Year |
|---|---|
Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Blotting, Western; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Diterpenes, Clerodane; Gastrointestinal Motility; Male; Mice; Naltrexone; Pain; Peroxidase; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, kappa; Salvia; Trinitrobenzenesulfonic Acid | 2012 |